Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Has FDA OK For Phase III Voclosporin Trialing In Lupus Nephritis

Executive Summary

Following consultations with the FDA, Canada's Aurinia Pharmaceuticals plans to run a single Phase III trial for voclosporin in lupus nephritis and then proceed to filing an NDA.

Advertisement

Related Content

New AURA Lupus Data Bode Well For Aurinia's Voclosporin In Future Phase III
Aurinia Names CEO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel